Drug Discovery– tag –

In Antibody-Drug Conjugates (ADCs), antibodies serve as targeting agents that deliver drugs to cancer cells. This article focuses on the "Variable Region," the key structure that enables antibodies to specifically recognize cancer antige...

Antibody-drug conjugates (ADCs) are next-generation therapeutics gaining attention, especially in oncology. In this second part, we introduce the three fundamental components of ADCs—antibody, linker, and payload—explaining their functio...

Summer Special｜Beginner-Friendly Intro Series Vol.2 (Part 1)What Are Antibodies? The Origin Story of ADCs – A Precision Cancer Weapon Welcome to Part 1 of our Summer Special Beginner Series Vol.2 on Morningglorysciences.This time, we’ll...

Summer Special｜Beginner-Friendly Intro Series Vol.1 (Part 2)Are They Safe? Global Competition and the Future of Anti-Obesity Drugs In Part 1, we explored what anti-obesity medications are, how GLP-1 works, and the key players in the cur...

Summer Special｜Beginner-Friendly Intro Series Vol.1 (Part 1)What Are Slimming Drugs? A Gentle Introduction to Anti-Obesity Medications Welcome to the Morningglorysciences Summer Special Beginner Series!This series is designed for reader...

BPI Technology Advances Targeted Protein Degradation — A Site-Specific Strategy to Accelerate Drug Discovery Introduction Targeted protein degradation (TPD) has emerged as a transformative strategy in drug discovery, offering a means to ...

A New Era in Flu Prevention? — CD388 Shows One-Shot Seasonal Protection Introduction Flu prevention has long relied on seasonal vaccines, but a new innovation may challenge that paradigm. CD388, a long-acting antiviral developed by Cidar...

Introduction Over the past decade, major Japanese pharmaceutical companies have undergone significant evolution amidst global competition. Daiichi Sankyo, Takeda, Otsuka, and Astellas have each leveraged their strengths to enhance compet...

Introduction Between 2015 and 2025, global pharmaceutical giants have expanded into innovative therapeutic areas and pursued internalization or adoption of novel technologies. Based on the strategic movements of 22 companies, this articl...

A study published in the June 2025 issue of Cancer Discovery reports a novel small-molecule strategy to restore the tumor suppressor function of mutant p53 proteins. This work was also featured in a companion Perspective article, highlig...

A study published in the June 2025 issue of Cancer Discovery reveals how cancer-associated fibroblasts (CAFs) promote metastatic progression in breast cancer by suppressing natural killer (NK) cell cytotoxicity. This work was selected fo...

A study published online in June 2025 in Cancer Discovery reveals that **T-cell–dependent tumor regression** is a key mechanism underlying the efficacy of KRAS G12D inhibitors in pancreatic ductal adenocarcinoma (PDAC). KRAS G12D is a ma...

A study published in the June 2025 issue of Cancer Discovery reveals that highly mutated cell clones carrying multiple driver mutations can persist for many years in esophageal squamous epithelium before progressing to esophageal squamou...

– Global Comparison and Future Perspectives in the Post-PRV Era – With the expiration of the U.S. FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program in 2024, a global debate has emerged about how to sustain innovation in ...

CAR T-cell therapy has revolutionized blood cancer treatment but traditionally relies on an ex vivo process—extracting T cells from patients, genetically modifying them outside the body, expanding them, and reinfusing them. This manufact...

A comprehensive review published in the June 2025 issue of Nature Biotechnology summarizes the current status of personalized mRNA cancer vaccine development. Neoantigen-based mRNA vaccines, tailored to individual patients' tumor mutatio...

🧒 Introduction: Why Focus on Pediatric Rare Diseases? Pediatric rare diseases often involve life-threatening conditions with few treatment options. In 2012, the U.S. introduced the Rare Pediatric Disease Priority Review Voucher (PRV) pro...

23andMe, once one of the largest direct-to-consumer (DTC) genomics companies with a vast database of genetic, familial, and self-reported health data, has entered bankruptcy proceedings. While Regeneron was initially seen as a potential ...

With the rapid evolution of artificial intelligence (AI), the concept of AI Drug Discovery has gained significant attention. Headlines often suggest that AI can now "create new drugs" or "automate drug development," raising expectations ...

A new study published in the June 12, 2025 issue of Nature reports that the small molecule PZL-A can directly restore the function of DNA polymerase gamma (POLγ), impaired by POLG mutations causing severe mitochondrial disorders. This wo...